ReviewIndian journal of ophthalmology2012
Glaucomatous neurodegeneration: an eye on tumor necrosis factor-alpha.
Review in Indian journal of ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Aqueous humor TGF-β2 levels in patients with open-angle glaucoma: A meta-analysis.Molecular vision · 2015Pooled it
- Roles of tumor necrosis factor alpha gene polymorphisms, tumor necrosis factor alpha level in aqueous humor, and the risks of open angle glaucoma: a meta-analysis.Molecular vision · 2013Pooled it
- TNFα-dependent modulation of WT1-MMP9 regulatory axis links developmental and inflammatory pathways in glaucoma.iScience · 2026Article
- Stem Cell-Based Therapies for Glaucoma Treatment: A Review Bridging the Gap in Veterinary Patients.International journal of molecular sciences · 2024Review
- A Reduction in Mitophagy Is Associated with Glaucomatous Neurodegeneration in Rodent Models of Glaucoma.International journal of molecular sciences · 2024Article
- Apoptosis in glaucoma: A new direction for the treatment of glaucoma (Review).Molecular medicine reports · 2024Review
- Optic Nerve Head Gene Transcription Sequelae to a Single Elevated IOP Exposure Provides Insights Into Known Responses to Chronically Elevated IOP.Investigative ophthalmology & visual science · 2023Article
- Electroacupuncture ameliorates inflammatory response induced by retinal ischemia-reperfusion injury and protects the retina through the DOR-BDNF/Trkb pathway.Frontiers in neuroanatomy · 2022Article
- Review
- Effect of depressive symptom and depressive disorder on glaucoma incidence in elderly.Scientific reports · 2021Article
- Progression and Pathology of Traumatic Optic Neuropathy From Repeated Primary Blast Exposure.Frontiers in neuroscience · 2019Article
- Association of increased levels of plasma tumor necrosis factor alpha with primary open-angle glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- Elevated levels of plasma tumor necrosis factor alpha in patients with pseudoexfoliation glaucoma.Clinical ophthalmology (Auckland, N.Z.) · 2018Article
- The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration.Frontiers in neuroscience · 2018Review
- Neuroinflammation in glaucoma: A new opportunity.Experimental eye research · 2017Review
- Genes of tumor necrosis factors and their receptors and the primary open angle glaucoma in the population of Central Russia.International journal of ophthalmology · 2017Article
- Analyzing cytokines as biomarkers to evaluate severity of glaucoma.International journal of ophthalmology · 2017Article
- Risk of open angle glaucoma due to tumor necrosis factor alpha gene polymorphisms.Electronic physician · 2016Article
- Present and New Treatment Strategies in the Management of Glaucoma.The open ophthalmology journal · 2015Article
- Biochemical changes and treatment in glaucoma.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma, a neurodegenerative disease, is currently being treated by modulation of one of its primary risk factors, the elevated intraocular pressure. Newer therapies that can provide direct neuroprotection to retinal ganglion cells are being extensively investigated. Tumor necrosis factor-α, a cytokine, has been recognized to play an important role in pro and antiapoptotic cellular events. In this paper we review the relevant literature to understand (1) The association of increased expression of tumor necrosis factor-α with glaucomatous neurodegeneraion, (2) Modulation of tumor necrosis factor-α expression by exposure to various risk factors of glaucoma, (3) Downstream cellular signaling mechanisms following interaction of tumor necrosis factor-α with its receptors and (4) Role of tumor necrosis factor-α as a possible target for therapeutic intervention in glaucoma. Literature was reviewed using PubMed search engine with relevant key words and a total of 82 English language papers published from 1990 to 2010 are included in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.